REDWOOD CITY, Calif. — August 6, 2025 — Leads & Copy — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced that Laurent Fischer, MD, President and CEO, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025, at 9:00 am EDT.
A live webcast of the fireside chat can be accessed in the Investors section of Adverum’s website. An archived replay will be available for at least 30 days following the presentation.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases, developing functional cures to restore vision and prevent blindness. Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections. Adverum is evaluating its gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), as a one-time injection for patients with neovascular or wet age-related macular degeneration.
Contact:
Adverum Investor Relations
Email: ir@adverum.com
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email: jawe@adverum.com
Source: Adverum Biotechnologies
